DIAGNOS Completes a Significant Private Placement
Today, DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) reached a major milestone by successfully closing a non-brokered private placement. This achievement is part of the company's mission to improve health care through the use of Artificial Intelligence (AI). The placement raised around $2.5 million by issuing 8,333,333 units, each priced at $0.30.
Private Placement Details
Each unit from this private placement includes one common share and one warrant. In connection with this closing, subscribers were issued a total of 8,333,333 Warrants. Each warrant allows the holder to buy an additional common share at a price of $0.40. This opportunity to exercise the warrants will be available for 18 months, with the period concluding on March 20, 2026.
Funding Prospective Innovations and Operations
The capital raised from this private placement will primarily be directed toward the development and commercialization of DIAGNOS's AI-based screening services. This investment is essential for advancing product development and supporting general administrative functions, ensuring the company remains a leader in the early detection of health concerns.
Compliance with Regulations and Security Hold
It's worth noting that all securities issued in this private placement will be subject to a statutory hold period, which is set to last until January 21, 2025. The completion of the private placement is dependent on obtaining all necessary approvals, including those from the TSX Venture Exchange.
Expression of Gratitude and Recognition
DIAGNOS would like to sincerely thank the family office that participated in this private placement. Their support highlights the strong confidence that investors have in DIAGNOS's vision and innovative approach within the healthcare sector.
Corrections on Recent Announcements
In a recent management information circular, there was an error in the first paragraph of Section 6 where a Record Date was incorrectly presented. To clarify, the Board of the Corporation has established the Record Date as the date to identify the registered holders of voting shares who are entitled to receive notice of the Meeting. All common shareholders as of this date are invited to take part in the Meeting.
About DIAGNOS and Its Innovations
DIAGNOS is a Canadian corporation dedicated to the early detection of critical health issues through its proprietary FLAIRE AI platform. This innovative technology allows for the rapid modification and development of applications, including CARA (Computer Assisted Retina Analysis). CARA utilizes advanced image enhancement algorithms to deliver clearer and more precise retinal images, making it an invaluable tool for efficiently screening large groups of patients.
With the recent financial boost from the private placement, DIAGNOS is well-positioned to continue its growth and further revolutionize the health screening landscape.
Frequently Asked Questions
What was the purpose of the private placement?
The private placement aimed to raise funds for product development and the commercialization of AI-based screening services.
How much money did DIAGNOS raise?
DIAGNOS raised gross proceeds of approximately $2.5 million from the private placement.
What are the benefits of the common share warrants issued?
The common share warrants allow subscribers to purchase additional shares at a set price, potentially providing further investment opportunities in the company.
What is the FLAIRE AI platform?
The FLAIRE AI platform is DIAGNOS's technology for early health issues detection, enabling efficient development of applications like CARA.
When is the hold period for the securities issued?
The securities issued as part of the private placement are subject to a statutory hold period lasting until January 21, 2025.
